BioSight

About:

Biosight is a private Phase 2 clinical stage biotech company developing innovative therapeutics for hematological.

Website: http://www.biosight-pharma.com/

Top Investors: Phoenix Financial, Trendlines Group, SBI Japan-Israel Innovation Fund, Arkin Holdings, Primera Capital

Description:

BioSight is a biopharmaceutical private company founded in 2000 and re launched in mid 2009, revolutionizing the research and development of innovative cancer targeted pro-drugs. BioSight has developed technology S2DOT TM and a pipeline of targeted pro-drugs, that can target and release chemotherapy drugs inside cancer cells, while significantly minimizing the systemic toxicity associated with conventional chemotherapy treatments.

Total Funding Amount:

$59M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Carmiel, HaZafon, Israel

Founded Date:

2000-01-01

Contact Email:

contact(AT)biosight-pharma.com

Founders:

Mark Gengrinovitch, Stela Gengrinovitch

Number of Employees:

11-50

Last Funding Date:

2020-12-02

IPO Status:

Private

Industries: